Advanced search
Publication Cover
Future Oncology Volume 5, 2009 - Issue 8
Submit an article Journal homepage
911
Views
1
CrossRef citations to date
0
Altmetric
Review

Mechanisms of the Epithelial–Mesenchymal Transition by TGF-β

Michael K WendtDepartment of Pharmacology, MS-8303, University of Colorado Denver, Anschutz Medical Campus, RC1 South Tower, Room L18–6110, 12801 East 17th Avenue, PO Box 6511, Aurora, CO80045, USA. [email protected]View further author information
,
Tressa M AllingtonDepartment of Pharmacology, MS-8303, University of Colorado Denver, Anschutz Medical Campus, RC1 South Tower, Room L18–6110, 12801 East 17th Avenue, PO Box 6511, Aurora, CO80045, USA. [email protected]View further author information
&
William P SchiemannDepartment of Pharmacology, MS-8303, University of Colorado Denver, Anschutz Medical Campus, RC1 South Tower, Room L18–6110, 12801 East 17th Avenue, PO Box 6511, Aurora, CO80045, USA. [email protected]Correspondence[email protected]
View further author information
Pages 1145-1168 | Published online: 26 Oct 2009

Bibliography

  • Baum B , SettlemanJ, QuinlanMP: Transitions between epithelial and mesenchymal states in development and disease.Semin. Cell Dev. Biol.19, 294–308 (2008).
  • Yang J , WeinbergRA: Epithelial–mesenchymal transition: at the crossroads of development and tumor metastasis.Dev. Cell.14, 818–829 (2008).
  • Elenbaas B , WeinbergRA: Heterotypic signaling between epithelial tumor cells and fibroblasts in carcinoma formation.Exp. Cell Res.264, 169–184 (2001).
  • Moustakas A , HeldinCH: Signaling networks guiding epithelial–mesenchymal transitions during embryogenesis and cancer progression.Cancer Sci.98, 1512–1520 (2007).
  • Zavadil J , BottingerEP: TGF-β and epithelial-to-mesenchymal transitions.Oncogene24, 5764–5774 (2005).
  • Thiery JP : Epithelial–mesenchymal transitions in development and pathologies.Curr. Opin. Cell Biol.15, 740–746 (2003).
  • Shook D , KellerR: Mechanisms, mechanics and function of epithelial–mesenchymal transitions in early development.Mech. Dev.120, 1351–1383 (2003).
  • Thiery JP : Epithelial–mesenchymal transitions in tumor progression.Nat. Rev. Cancer2, 442–454 (2002).
  • Willis BC , BorokZ: TGF-β-induced EMT: mechanisms and implications for fibrotic lung disease.Am. J. Physiol. Lung Cell. Mol. Physiol.293, L525–L534 (2007).
  • Blobe GC , SchiemannWP, LodishHF: Role of TGF-β in human disease.N. Engl. J. Med.342, 1350–1358 (2000).
  • Galliher AJ , NeilJR, SchiemannWP: Role of TGF-β in cancer progression.Future Oncol.2, 743–763 (2006).
  • Massague J , GomisRR: The logic of TGF-β signaling.FEBS Lett.580, 2811–2820 (2006).
  • Siegel PM , MassagueJ: Cytostatic and apoptotic actions of TGF-β in homeostasis and cancer.Nat. Rev. Cancer3, 807–821 (2003).
  • Savagner P : Leaving the neighborhood: molecular mechanisms involved during epithelial–mesenchymal transition.Bioessays23, 912–923 (2001).
  • Miettinen PJ , EbnerR, LopezAR, DerynckR: TGF-β induced transdifferentiation of mammary epithelial cells to mesenchymal cells: involvement of type I receptors.J. Cell Biol.127, 2021–2036 (1994).
  • Kaartinen V , VonckenJW, ShulerCet al.: Abnormal lung development and cleft palate in mice lacking TGF-β3 indicates defects of epithelial–mesenchymal interaction.Nature Genet.11, 415–421 (1995).
  • Romano LA , RunyanRB: Slug is an essential target of TGF-β2 signaling in the developing chicken heart.Dev. Biol.223, 91–102 (2000).
  • Saika S , Kono-SaikaS, OhnishiYet al.: Smad3 signaling is required for epithelial–mesenchymal transition of lens epithelium after injury.Am. J. Pathol.164, 651–663 (2004).
  • Saika S , Kono-SaikaS, TanakaTet al.: Smad3 is required for dedifferentiation of retinal pigment epithelium following retinal detachment in mice.Lab. Invest.84, 1245–1258 (2004).
  • Sato M , MuragakiY, SaikaS, RobertsAB, OoshimaA: Targeted disruption of TGF-β1/Smad3 signaling protects against renal tubulointerstitial fibrosis induced by unilateral ureteral obstruction.J. Clin. Invest.112, 1486–1494 (2003).
  • Feng XH , DerynckR: Specificity and versatility in TGF-β signaling through Smads.Annu. Rev. Cell Dev. Biol.21, 659–693 (2005).
  • Moustakas A , HeldinCH: Non-Smad TGF-β signals.J. Cell Sci.118, 3573–3584 (2005).
  • Shi Y , MassagueJ: Mechanisms of TGF-β signaling from cell membrane to the nucleus.Cell113, 685–700 (2003).
  • Tsukazaki T , ChiangTA, DavisonAF, AttisanoL, WranaJL: SARA, a FYVE domain protein that recruits Smad2 to the TGF-β receptor.Cell95, 779–791 (1998).
  • Miura S , TakeshitaT, AsaoHet al.: Hgs (Hrs), a FYVE domain protein, is involved in Smad signaling through cooperation with SARA.Mol. Cell Biol.20, 9346–9355 (2000).
  • Hocevar BA , SmineA, XuXX, HowePH: The adaptor molecule Disabled-2 links the TGF-β receptors to the Smad pathway.EMBO J.20, 2789–2801 (2001).
  • Hayashi H , AbdollahS, QiuYet al.: The MAD-related protein Smad7 associates with the TGF-β receptor and functions as an antagonist of TGF-β signaling.Cell89, 1165–1173 (1997).
  • Nakao A , AfrakhtM, MorenAet al.: Identification of Smad7, a TGF-β-inducible antagonist of TGF-β signalling.Nature389, 631–635 (1997).
  • Souchelnytskyi S , NakayamaT, NakaoAet al.: Physical and functional interaction of murine and Xenopus Smad7 with bone morphogenetic protein receptors and TGF-β receptors.J. Biol. Chem.273, 25364–25370 (1998).
  • Ebisawa T , FukuchiM, MurakamiGet al.: Smurf1 interacts with TGF-β type I receptor through Smad7 and induces receptor degradation.J. Biol. Chem.276, 12477–12480 (2001).
  • Kavsak P , RasmussenRK, CausingCGet al.: Smad7 binds to Smurf2 to form an E3 ubiquitin ligase that targets the TGF-β receptor for degradation.Mol. Cell6, 1365–1375 (2000).
  • Datta PK , MosesHL: STRAP and Smad7 synergize in the inhibition of TGF-β signaling.Mol. Cell. Biol.20, 3157–3167 (2000).
  • Ibarrola N , KratchmarovaI, NakajimaDet al.: Cloning of a novel signaling molecule, AMSH-2, that potentiates TGF-β signaling.BMC Cell Biol.5, 2 (2004).
  • Koinuma D , ShinozakiM, KomuroAet al.: Arkadia amplifies TGF-β superfamily signalling through degradation of Smad7.EMBO J.22, 6458–6470 (2003).
  • Liu FY , LiXZ, PengYM, LiuH, LiuYH: Arkadiα-SMAd7-mediated positive regulation of TGF-β signaling in a rat model of tubulointerstitial fibrosis.Am. J. Nephrol.27, 176–183 (2007).
  • Liu W , RuiH, WangJet al.: Axin is a scaffold protein in TGF-β signaling that promotes degradation of Smad7 by Arkadia.EMBO J.25, 1646–1658 (2006).
  • Bakin AV , RinehartC, TomlinsonAK, ArteagaCL: p38 mitogen-activated protein kinase is required for TGF-β-mediated fibroblastic transdifferentiation and cell migration.J. Cell Sci.115, 3193–3206 (2002).
  • Bakin AV , TomlinsonAK, BhowmickNA, MosesHL, ArteagaCL: Phosphatidylinositol 3-kinase function is required for TGF-β-mediated epithelial to mesenchymal transition and cell migration.J. Biol. Chem.275, 36803–36810 (2000).
  • Bhowmick NA , ZentR, GhiassiM, McDonnellM, MosesHL: Integrin β1 signaling is necessary for TGF-β activation of p38MAPK and epithelial plasticity.J. Biol. Chem.276, 46707–46713 (2001).
  • Lamouille S , DerynckR: Cell size and invasion in TGF-β induced epithelial to mesenchymal transition is regulated by activation of the mTOR pathway.J. Cell Biol.178, 437–451 (2007).
  • Perlman R , SchiemannWP, BrooksMW, LodishHF, WeinbergRA: TGF-β-induced apoptosis is mediated by the adapter protein Daxx that facilitates JNK activation.Nat. Cell Biol.3, 708–714 (2001).
  • Zavadil J , BitzerM, LiangDet al.: Genetic programs of epithelial cell plasticity directed by TGF-β.Proc. Natl Acad. Sci. USA98, 6686–6691 (2001).
  • Galliher AJ , SchiemannWP: β3 integrin and Src facilitate TGF-β mediated induction of epithelial–mesenchymal transition in mammary epithelial cells.Breast Cancer Res.8, R42 (2006).
  • Galliher AJ , SchiemannWP: Src phosphorylates Tyr284 in TGF-β type II receptor and regulates TGF-β stimulation of p38 MAPK during breast cancer cell proliferation and invasion.Cancer Res.67, 3752–3758 (2007).
  • Galliher-Beckley AJ , SchiemannWP: Grb2 binding to Tyr284 in TGF-β is essential for mammary tumor growth and metastasis stimulated by TGF-β.Carcinogenesis29, 244–251 (2008).
  • Azuma M , MotegiK, AotaK, YamashitaT, YoshidaH, SatoM: TGF-β1 inhibits NF-κB activity through induction of IκBα expression in human salivary gland cells: a possible mechanism of growth suppression by TGF-β1.Exp. Cell Res.250, 213–222 (1999).
  • Neil JR , SchiemannWP: Altered TAB1:IkB kinase interaction promotes TGF-β-mediated NF-κB activation during breast cancer progression.Cancer Res.68, 1462–1470 (2008).
  • Arsura M , PantaGR, BilyeuJDet al.: Transient activation of NF-κB through a TAK1//IKK kinase pathway by TGF-β1 inhibits AP-1//SMAD signaling and apoptosis: implications in liver tumor formation.Oncogene22, 412–425 (2003).
  • Kim DW , SovakMA, ZanieskiGet al.: Activation of NF-κB/Rel occurs early during neoplastic transformation of mammary cells.Carcinogenesis21, 871–879 (2000).
  • Park J-I , LeeM-G, ChoKet al.: TGF-β1 activates interleukin-6 expression in prostate cancer cells through the synergistic collaboration of the Smad2, p38-NF-κB, JNK, and Ras signaling pathways. Oncogene22, 4314–4332 (2003).
  • Rayet B , GelinasC: Aberrant Rel/NF-κB genes and activity in human cancer.Oncogene18, 6938–6947 (1999).
  • Horowitz JC , RogersDS, SharmaVet al.: Combinatorial activation of FAK and AKT by TGF-β1 confers an anoikis-resistant phenotype to myofibroblasts.Cell Signal.19, 761–771 (2007).
  • Thannickal VJ , LeeDY, WhiteESet al.: Myofibroblast differentiation by TGF-β1 is dependent on cell adhesion and integrin signaling via focal adhesion kinase.J. Biol. Chem.278, 12384–12389 (2003).
  • Park SS , EomYW, KimEHet al.: Involvement of c-Src kinase in the regulation of TGF-β1-induced apoptosis.Oncogene23, 6272–6281 (2004).
  • Wang S , WilkesMC, LeofEB, HirschbergR: Imatinib mesylate blocks a non-Smad TGF-β pathway and reduces renal fibrogenesis in vivo.FASEB J.19, 1–11 (2005).
  • Wilkes MC , LeofEB: TGF-β activation of c-Abl is independent of receptor internalization and regulated by phosphatidylinositol 3-kinase and PAK2 in mesenchymal cultures.J. Biol. Chem.281, 27846–27854 (2006).
  • Ebnet K , SuzukiA, OhnoS, VestweberD: Junctional adhesion molecules (JAMs): more molecules with dual functions?J. Cell Sci.117, 19–29 (2004).
  • Schneeberger EE , LynchRD: The tight junction: a multifunctional complex.Am. J. Physiol. Cell. Physiol.286, C1213–C1228 (2004).
  • Itoh M , BissellMJ: The organization of tight junctions in epithelia: implications for mammary gland biology and breast tumorigenesis.J. Mammary Gland Biol. Neoplasia8, 449–462 (2003).
  • Bose R , WranaJL: Regulation of Par6 by extracellular signals.Curr. Opin. Cell Biol.18, 206–212 (2006).
  • Ozdamar B , BoseR, Barrios-RodilesM, WangHR, ZhangY, WranaJL: Regulation of the polarity protein Par6 by TGF-β receptors controls epithelial cell plasticity.Science307, 1603–1609 (2005).
  • Takaishi K , SasakiT, KotaniH, NishiokaH, TakaiY: Regulation of cell–cell adhesion by Rac and Rho small G proteins in MDCK Cells.J. Cell Biol.139, 1047–1059 (1997).
  • Niessen CM : Tight junctions/adherens junctions: basic structure and function.J. Invest. Dermatol.127, 2525–2532 (2007).
  • Ridley AJ , HallA: The small GTP-binding protein Rho regulates the assembly of focal adhesions and actin stress fibers in response to growth factors.Cell70, 389–399 (1992).
  • Bhowmick NA , GhiassiM, BakinAet al.: TGF-β1 mediates epithelial to mesenchymal transdifferentiation through a RhoA-dependent mechanism.Mol. Biol. Cell12, 27–36 (2001).
  • Mueller MM , FusenigNE: Friends or foes - bipolar effects of the tumour stroma in cancer.Nat. Rev. Cancer4, 839–849 (2004).
  • Kaplan RN , RafiiS, LydenD: Preparing the ‘soil‘: the premetastatic niche.Cancer Res.66, 11089–11093 (2006).
  • Tlsty TD , CoussensLM: Tumor stroma and regulation of cancer development.Annu. Rev. Pathol.1, 119–150 (2006).
  • Park CC , BissellMJ, Barcellos-HoffMH: The influence of the microenvironment on the malignant phenotype.Mol. Med. Today6, 324–329 (2000).
  • Egeblad M , WerbZ: New functions for the matrix metalloproteinases in cancer progression.Nat. Rev. Cancer2, 161–174 (2002).
  • Mott JD , WerbZ: Regulation of matrix biology by matrix metalloproteinases.Curr. Opin. Cell Biol.16, 558–564 (2004).
  • Duivenvoorden WC , HirteHW, SinghG: TGF-β1 acts as an inducer of matrix metalloproteinase expression and activity in human bone-metastasizing cancer cells.Clin. Exp. Metastasis17, 27–34 (1999).
  • Kim ES , SohnYW, MoonA: TGF-β-induced transcriptional activation of MMP-2 is mediated by activating transcription factor (ATF)2 in human breast epithelial cells.Cancer Lett.252, 147–156 (2007).
  • Coussens LM , TinkleCL, HanahanD, WerbZ: MMP-9 supplied by bone marrow-derived cells contributes to skin carcinogenesis.Cell103, 481–490 (2000).
  • Paszek MJ , WeaverVM: The tension mounts: mechanics meets morphogenesis and malignancy.J. Mammary Gland Biol. Neoplasia.9, 325–342 (2004).
  • Anderson AR , WeaverAM, CummingsPT, QuarantaV: Tumor morphology and phenotypic evolution driven by selective pressure from the microenvironment.Cell127, 905–915 (2006).
  • Sternlicht MD , BissellMJ, WerbZ: The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter.Oncogene19, 1102–1113 (2000).
  • Sternlicht MD , LochterA, SympsonCJet al.: The stromal proteinase MMP3/stromelysin-1 promotes mammary carcinogenesis.Cell98, 137–146 (1999).
  • Radisky DC , LevyDD, LittlepageLEet al.: Rac1b and reactive oxygen species mediate MMP-3-induced EMT and genomic instability.Nature436, 123–127 (2005).
  • Radisky DC , KennyPA, BissellMJ: Fibrosis and cancer: do myofibroblasts come also from epithelial cells via EMT?J. Cell Biochem.101, 830–839 (2007).
  • Huber MA , KrautN, BeugH: Molecular requirements for epithelial–mesenchymal transition during tumor progression.Curr. Opin. Cell Biol.17, 548–558 (2005).
  • Gotzmann J , MikulaM, EgerAet al.: Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis.Mutat. Res.566, 9–20 (2004).
  • Jechlinger M , GrunertS, BeugH: Mechanisms in epithelial plasticity and metastasis: insights from 3D cultures and expression profiling.J. Mammary Gland Biol. Neoplasia7, 415–432 (2002).
  • Cavallaro U , NiedermeyerJ, FuxaM, ChristoforiG: N-CAM modulates tumour-cell adhesion to matrix by inducing FGF-receptor signalling.Nat. Cell Biol.3, 650–657 (2001).
  • Lehembre F , YilmazM, WickiAet al.: NCAM-induced focal adhesion assembly: a functional switch upon loss of E-cadherin.EMBO J.27, 2603–2615 (2008).
  • Illman SA , LehtiK, Keski-OjaJ, LohiJ: Epilysin (MMP-28) induces TGF-β mediated epithelial to mesenchymal transition in lung carcinoma cells.J. Cell Sci.119, 3856–3865 (2006).
  • Illman SA , LohiJ, Keski-OjaJ: Epilysin (MMP-28) – structure, expression and potential functions.Exp. Dermatol.17, 897–907 (2008).
  • Harbeck N , KatesRE, SchmittMet al.: Urokinase-type plasminogen activator and its inhibitor type 1 predict disease outcome and therapy response in primary breast cancer.Clin. Breast Cancer5, 348–352 (2004).
  • Duffy MJ , DugganC: The urokinase plasminogen activator system: a rich source of tumor markers for the individualized management of patients with cancer.Clin. Biochem.37, 541–548 (2004).
  • Mitra SK , LimST, ChiA, SchlaepferDD: Intrinsic focal adhesion kinase activity controls orthotopic breast carcinoma metastasis via the regulation of urokinase plasminogen activator expression in a syngenetic tumor model.Oncogene25, 4429–4440 (2006).
  • Lin SW , KeFC, HsiaoPW, LeePP, LeeMT, HwangJJ: Critical involvement of ILK in TGF-β1-stimulated invasion/migration of human ovarian cancer cells is associated with urokinase plasminogen activator system.Exp. Cell Res.313, 602–613 (2007).
  • Lester RD , JoM, MontelV, TakimotoS, GoniasSL: uPAR induces epithelial mesenchymal transition in hypoxic breast cancer cells.J. Cell Biol.178, 425–436 (2007).
  • Santibanez JF : JNK mediates TGF-β1-induced epithelial mesenchymal transdifferentiation of mouse transformed keratinocytes.FEBS Lett.580, 5385–5391 (2006).
  • Whitley BR , ChurchFC: Wound-induced migration of MDA-MB-435 and SKOV-3 cancer cells is regulated by plasminogen activator inhibitor-1.Int. J. Oncol.27, 749–757 (2005).
  • Binder BR , ChristG, GruberFet al.: Plasminogen activator inhibitor 1: physiological and pathophysiological roles.News Physiol. Sci.17, 56–61 (2002).
  • Shetty S , ShettyP, IdellS, VelusamyT, BhandaryYP, ShettyRS: Regulation of plasminogen activator inhibitor-1 expression by tumor suppressor protein p53.J. Biol. Chem.283, 19570–19580 (2008).
  • Kortlever RM , BernardsR: Senescence, wound healing and cancer: the PAI-1 connection.Cell Cycle5, 2697–2703 (2006).
  • Whitley BR , PalmieriD, TwerdiCD, ChurchFC: Expression of active plasminogen activator inhibitor-1 reduces cell migration and invasion in breast and gynecological cancer cells.Exp. Cell Res.296, 151–162 (2004).
  • Descotes F , RicheB, SaezSet al.: Plasminogen activator inhibitor type 1 is the most significant of the usual tissue prognostic factors in node-negative breast ductal adenocarcinoma independent of urokinase-type plasminogen activator.Clin. Breast Cancer8, 168–177 (2008).
  • Wienke D , DaviesGC, JohnsonDAet al.: The collagen receptor Endo180 (CD280) is expressed on basal-like breast tumor cells and promotes tumor growth in vivo.Cancer Res.67, 10230–10240 (2007).
  • Kim ES , KimMS, MoonA: TGF-β in conjunction with H-Ras activation promotes malignant progression of MCF10A breast epithelial cells.Cytokine29, 84–91 (2005).
  • Ignotz RA , MassagueJ: TGF-β stimulates the expression of fibronectin and collagen and their incorporation into the extracellular matrix.J. Biol. Chem.261, 4337–4345 (1986).
  • Xie L , LawB, AakreMet al.: TGF-β-regulated gene expression in a mouse mammary gland epithelial cell line.Breast Cancer Res.5, R187–R198 (2003).
  • Maschler S , WirlG, SpringHet al.: Tumor cell invasiveness correlates with changes in integrin expression and localization.Oncogene24, 2032–2041 (2005).
  • Kang Y , MassagueJ: Epithelial–mesenchymal transitions: Twist in development and metastasis.Cell118, 277–279 (2004).
  • Bremnes RM , VeveR, HirschFR, FranklinWA: The E-cadherin cell–cell adhesion complex and lung cancer invasion, metastasis, and prognosis.Lung Cancer36, 115–124 (2002).
  • Graff JR , GreenbergVE, HermanJGet al.: Distinct patterns of E-cadherin CpG island methylation in papillary, follicular, Hurthle’s cell, and poorly differentiated human thyroid carcinoma.Cancer Res.58, 2063–2066 (1998).
  • Comijn J , BerxG, VermassenPet al.: The two-handed E box binding zinc finger protein SIP1 downregulates E-cadherin and induces invasion.Mol. Cell7, 1267–1278 (2001).
  • Peinado H , OlmedaD, CanoA: Snail, Zeb and bHLH factors in tumour progression: an alliance against the epithelial phenotype?Nat. Rev. Cancer7, 415–428 (2007).
  • Cano A , Perez-MorenoMA, RodrigoIet al.: The transcription factor snail controls epithelial–mesenchymal transitions by repressing E-cadherin expression.Nat. Cell Biol.2, 76–83 (2000).
  • Thuault S , ValcourtU, PetersenM, ManfiolettiG, HeldinCH, MoustakasA: TGF-β employs HMGA2 to elicit epithelial–mesenchymal transition.J. Cell Biol.174, 175–183 (2006).
  • Hazan RB , PhillipsGR, QiaoRF, NortonL, AaronsonSA: Exogenous expression of N-cadherin in breast cancer cells induces cell migration, invasion, and metastasis.J. Cell Biol.148, 779–790 (2000).
  • Gravdal K , HalvorsenOJ, HaukaasSA, AkslenLA: A switch from E-cadherin to N-cadherin expression indicates epithelial to mesenchymal transition and is of strong and independent importance for the progress of prostate cancer.Clin. Cancer Res.13, 7003–7011 (2007).
  • Pyo SW , HashimotoM, KimYSet al.: Expression of E-cadherin, P-cadherin and N-cadherin in oral squamous cell carcinoma: correlation with the clinicopathologic features and patient outcome.J. Craniomaxillofac. Surg.35, 1–9 (2007).
  • Yang L , HuangJ, RenXet al.: Abrogation of TGF-β signaling in mammary carcinomas recruits Gr-1+CD11b+ myeloid cells that promote metastasis.Cancer Cell.13, 23–35 (2008).
  • Nam JS , TerabeM, MamuraMet al.: An anti-TGF-β antibody suppresses metastasis via cooperative effects on multiple cell compartments.Cancer Res.68, 3835–3843 (2008).
  • Grunert S , JechlingerM, BeugH: Diverse cellular and molecular mechanisms contribute to epithelial plasticity and metastasis.Nat. Rev. Mol. Cell Biol.4, 657 (2003).
  • Masszi A , Di CianoC, SirokmanyGet al.: Central role for Rho in TGF-β1-induced α-smooth muscle actin expression during epithelial–mesenchymal transition.Am. J. Physiol. Renal Physiol.284, F911–F924 (2003).
  • Yazhou C , WenlvS, WeidongZ, LicunW: Clinicopathological significance of stromal myofibroblasts in invasive ductal carcinoma of the breast.Tumour Biol.25, 290–295 (2004).
  • Cary LA , GuanJL: Focal adhesion kinase in integrin-mediated signaling.Front. Biosci.4, D102–D113 (1999).
  • Cary LA , HanDC, GuanJL: Integrin-mediated signal transduction pathways.Histol. Histopathol.14, 1001–1009 (1999).
  • Schwartz MA , GinsbergMH: Networks and crosstalk: integrin signalling spreads.Nat. Cell Biol.4, E65–E68 (2002).
  • Hood JD , ChereshDA: Role of integrins in cell invasion and migration.Nat. Rev. Cancer.2, 91–100 (2002).
  • Ginsberg MH , PartridgeA, ShattilSJ: Integrin regulation.Curr. Opin. Cell Biol.17, 509–516 (2005).
  • Guo W , GiancottiFG: Integrin signalling during tumour progression.Nat. Rev. Mol. Cell Biol.5, 816–826 (2004).
  • Sieg DJ , HauckCR, IlicDet al.: FAK integrates growth-factor and integrin signals to promote cell migration.Nat. Cell Biol.2, 249–256 (2000).
  • Chen SY , ChenHC: Direct interaction of focal adhesion kinase (FAK) with Met is required for FAK to promote hepatocyte growth factor-induced cell invasion.Mol. Cell. Biol.26, 5155–5167 (2006).
  • Mizejewski GJ : Role of integrins in cancer: survey of expression patterns.Proc. Soc. Exp. Biol. Med.222, 124–138 (1999).
  • Sheppard D , CohenDS, WangA, BuskM: TGF-β differentially regulates expression of integrin subunits in guinea pig airway epithelial cells.J. Biol. Chem.267, 17409–17414 (1992).
  • Kumar NM , SigurdsonSL, SheppardD, Lwebuga-MukasaJS: Differential modulation of integrin receptors and extracellular matrix laminin by TGF-β1 in rat alveolar epithelial cells.Exp. Cell Res.221, 385–394 (1995).
  • Wang A , YokosakiY, FerrandoR, BalmesJ, SheppardD: Differential regulation of airway epithelial integrins by growth factors.Am. J. Respir. Cell Mol. Biol.15, 664–672 (1996).
  • Munger JS , HuangX, KawakatsuHet al.: The integrin αvβ6 binds and activates latent TGF-β1: a mechanism for regulating pulmonary inflammation and fibrosis.Cell96, 319–328 (1999).
  • Jenkins RG , SuX, SuGet al.: Ligation of protease-activated receptor 1 enhances αvβ6 integrin-dependent TGF-β activation and promotes acute lung injury.J. Clin. Invest.116, 1606–1614 (2006).
  • Neurohr C , NishimuraSL, SheppardD: Activation of TGF-β by the integrin αvβ8 delays epithelial wound closure.Am. J. Respir. Cell Mol. Biol.35, 252–259 (2006).
  • Morris DG , HuangX, KaminskiNet al.: Loss of integrin αvβ6-mediated TGF-β activation causes MMP12-dependent emphysema.Nature422, 169–173 (2003).
  • Mu D , CambierS, FjellbirkelandLet al.: The integrin αvβ8 mediates epithelial homeostasis through MT1-MMP-dependent activation of TGF-β1.J. Cell Biol.157, 493–507 (2002).
  • Knight PA , WrightSH, BrownJK, HuangX, SheppardD, MillerHR: Enteric expression of the integrin αvβ6 is essential for nematode-induced mucosal mast cell hyperplasia and expression of the granule chymase, mouse mast cell protease-1.Am. J. Pathol.161, 771–779 (2002).
  • Kim KK , KuglerMC, WoltersPJet al.: Alveolar epithelial cell mesenchymal transition develops in vivo during pulmonary fibrosis and is regulated by the extracellular matrix.Proc. Natl Acad. Sci. USA103, 13180–13185 (2006).
  • Bates RC , BellovinDI, BrownCet al.: Transcriptional activation of integrin β6 during the epithelial–mesenchymal transition defines a novel prognostic indicator of aggressive colon carcinoma.J. Clin. Invest.115, 339–347 (2005).
  • Ma LJ , YangH, GaspertAet al.: TGF-β-dependent and -independent pathways of induction of tubulointerstitial fibrosis in β6(-/-) mice.Am. J. Pathol.163, 1261–1273 (2003).
  • Owens DM , BroadS, YanX, BenitahSA, WattFM: Suprabasal α5β1 integrin expression stimulates formation of epidermal squamous cell carcinomas without disrupting TGF-β signaling or inducing spindle cell tumors.Mol. Carcinog.44, 60–66 (2005).
  • Kostenuik PJ , SinghG, OrrFW: TGF-β upregulates the integrin-mediated adhesion of human prostatic carcinoma cells to type I collagen.Clin. Exp. Metastasis15, 41–52 (1997).
  • Giannelli G , FransveaE, MarinosciFet al.: TGF-β1 triggers hepatocellular carcinoma invasiveness via α3β1 integrin.Am. J. Pathol.161, 183–193 (2002).
  • Giannelli G , BergaminiC, FransveaE, SgarraC, AntonaciS: Laminin-5 with TGF-β1 induces epithelial to mesenchymal transition in hepatocellular carcinoma.Gastroenterology129, 1375–1383 (2005).
  • Sloan EK , PouliotN, StanleyKLet al.: Tumor-specific expression of αvβ3 integrin promotes spontaneous metastasis of breast cancer to bone.Breast Cancer Res.8, R20 (2006).
  • Bandyopadhyay A , AgyinJK, WangLet al.: Inhibition of pulmonary and skeletal metastasis by a TGF-β type I receptor kinase inhibitor.Cancer Res.66, 6714–6721 (2006).
  • Nakamura K , YanoH, SchaeferE, SabeH: Different modes and qualities of tyrosine phosphorylation of Fak and Pyk2 during epithelial–mesenchymal transdifferentiation and cell migration: analysis of specific phosphorylation events using site-directed antibodies.Oncogene20, 2626–2635 (2001).
  • Liu S , Shi-wenX, KennedyLet al.: FAK is required for TGF-β-induced JNK phosphorylation in fibroblasts: implications for acquisition of a matrix-remodeling phenotype.Mol. Biol. Cell.18, 2169–2178 (2007).
  • Cicchini C , LaudadioI, CitarellaFet al.: TGF-β-induced EMT requires focal adhesion kinase (FAK) signaling.Exp. Cell Res.314, 143 (2008).
  • Wendt MK , SchiemannWP: Therapeutic targeting of the focal adhesion complex prevents oncogenic TGF-β signaling and metastasis.Breast Cancer Res.11(5), R68 (2009).
  • Kim W , Seok KangY, Soo KimJ, ShinN-Y, HanksSK, SongWK: The integrin-coupled signaling adaptor p130Cas suppresses Smad3 function in TGF-β signaling.Mol. Biol. Cell.19, 2135–2146 (2008).
  • Cabodi S , TinnirelloA, Di StefanoPet al.: p130Cas as a new regulator of mammary epithelial cell proliferation, survival, and HER2-Neu oncogene-dependent breast tumorigenesis.Cancer Res.66, 4672–4680 (2006).
  • Tumbarello DA , BrownMC, HeteySE, TurnerCE: Regulation of paxillin family members during epithelial–mesenchymal transformation: a putative role for paxillin δ.J. Cell Sci.118, 4849–4863 (2005).
  • Fujimoto N , YehS, KangHYet al.: Cloning and characterization of androgen receptor coactivator, ARA55, in human prostate.J. Biol. Chem.274, 8316–8321 (1999).
  • Guerrero-Santoro J , YangL, StallcupMR, DeFrancoDB: Distinct LIM domains of Hic-5/ARA55 are required for nuclear matrix targeting and glucocorticoid receptor binding and coactivation.J. Cell Biochem.92, 810–819 (2004).
  • Yang L , GuerreroJ, HongH, DeFrancoDB, StallcupMR: Interaction of the Tau2 transcriptional activation domain of glucocorticoid receptor with a novel steroid receptor coactivator, Hic-5, which localizes to both focal adhesions and the nuclear matrix.Mol. Biol. Cell.11, 2007–2018 (2000).
  • Tumbarello DA , TurnerCE: Hic-5 contributes to epithelial–mesenchymal transformation through a RhoA/ROCK-dependent pathway.J. Cell Physiol.211, 736–747 (2007).
  • Mok SC , WongKK, ChanRKet al.: Molecular cloning of differentially expressed genes in human epithelial ovarian cancer.Gynecol. Oncol.52, 247–252 (1994).
  • Mok SC , ChanWY, WongKKet al.: DOC-2, a candidate tumor suppressor gene in human epithelial ovarian cancer.Oncogene16, 2381–2387 (1998).
  • Prunier C , HocevarBA, HowePH: Wnt signaling: physiology and pathology.Growth Factors22, 141–150 (2004).
  • Prunier C , HowePH: Disabled-2 (Dab2) is required for TGF-β-induced epithelial to mesenchymal transition (EMT).J. Biol. Chem.280, 17540–17548 (2005).
  • Hocevar BA , PrunierC, HowePH: Disabled-2 (Dab2) mediates TGF-β-stimulated fibronectin synthesis through TGF-β-activated kinase 1 and activation of the JNK pathway.J. Biol. Chem.280, 25920–25927 (2005).
  • Sorrentino A , ThakurN, GrimsbySet al.: The type I TGF-β receptor engages TRAF6 to activate TAK1 in a receptor kinase-independent manner.Nat. Cell Biol.10, 1199–1207 (2008).
  • Yamashita M , FatyolK, JinC, WangX, LiuZ, ZhangYE: TRAF6 mediates Smad-independent activation of JNK and p38 by TGF-β.Mol. Cell31, 918–924 (2008).
  • Gal A , SjoblomT, FedorovaL, ImrehS, BeugH, MoustakasA: Sustained TGF-β exposure suppresses Smad and non-Smad signalling in mammary epithelial cells, leading to EMT and inhibition of growth arrest and apoptosis.Oncogene27, 1218–1230 (2008).
  • Hall A : Rho GTPases and the control of cell behaviour.Biochem. Soc. Trans.33, 891–895 (2005).
  • Hall A , NobesCD: Rho GTPases: molecular switches that control the organization and dynamics of the actin cytoskeleton.Philos. Trans. R. Soc. Lond. B. Biol. Sci.355, 965–970 (2000).
  • Sander EE , ten KloosterJP, van DelftS, van der KammenRA, CollardJG: Rac downregulates Rho activity: reciprocal balance between both GTPases determines cellular morphology and migratory behavior.J. Cell Biol.147, 1009–1022 (1999).
  • Cho HJ , YooJ: Rho activation is required for TGF-β-induced epithelial–mesenchymal transition in lens epithelial cells.Cell Biol. Int.31, 1225–1230 (2007).
  • Massague J : How cells read TGF-β signals.Nat. Rev. Mol. Cell. Biol.1, 169–178 (2000).
  • Murillo MM , del CastilloG, SanchezA, FernandezM, FabregatI: Involvement of EGF receptor and c-Src in the survival signals induced by TGF-β1 in hepatocytes.Oncogene24, 4580–4587 (2005).
  • Jechlinger M , SommerA, MorigglRet al.: Autocrine PDGFR signaling promotes mammary cancer metastasis.J. Clin. Invest.116, 1561–1570 (2006).
  • Dedhar S , WilliamsB, HanniganG: Integrin-linked kinase (ILK): a regulator of integrin and growth-factor signalling.Trends. Cell Biol.9, 319–323 (1999).
  • Hannigan G , TroussardAA, DedharS: Integrin-linked kinase: a cancer therapeutic target unique among its ILK.Nat. Rev. Cancer.5, 51–63 (2005).
  • Hehlgans S , HaaseM, CordesN: Signalling via integrins: implications for cell survival and anticancer strategies.Biochim. Biophys. Acta.1775, 163–180 (2007).
  • White DE , CardiffRD, DedharS, MullerWJ: Mammary epithelial-specific expression of the integrin-linked kinase (ILK) results in the induction of mammary gland hyperplasias and tumors in transgenic mice.Oncogene20, 7064–7072 (2001).
  • Somasiri A , HowarthA, GoswamiD, DedharS, RoskelleyCD: Overexpression of the integrin-linked kinase mesenchymally transforms mammary epithelial cells.J. Cell Sci.114, 1125–1136 (2001).
  • Lee YI , KwonYJ, JooCK: Integrin-linked kinase function is required for TGF-β-mediated epithelial to mesenchymal transition.Biochem. Biophys. Res. Commun.316, 997–1001 (2004).
  • Karin M : NF-κB in cancer development and progression.Nature441, 431 (2006).
  • Huber MA , AzoiteiN, BaumannBet al.: NF-κB is essential for epithelial–mesenchymal transition and metastasis in a model of breast cancer progression.J. Clin. Invest.114, 569–581 (2004).
  • Chua HL , Bhat-NakshatriP, ClareSE, MorimiyaA, BadveS, NakshatriH: NF-κB represses E-cadherin expression and enhances epithelial to mesenchymal transition of mammary epithelial cells: potential involvement of ZEB-1 and ZEB-2.Oncogene26, 711 (2006).
  • Sovak MA , ArsuraM, ZanieskiG, KavanaghKT, SonensheinGE: The inhibitory effects of TGF-β1 on breast cancer cell proliferation are mediated through regulation of aberrant NF-κB/Rel expression.Cell Growth Differ.10, 537–544 (1999).
  • Neil JR , JohnsonKM, NemenoffRA, SchiemannWP: Cox-2 inactivates Smad signaling and enhances EMT stimulated by TGF-β through a PGE2-dependent mechanisms.Carcinogenesis29, 2227–2235 (2008).
  • Xie L , LawBK, ChytilAM, BrownKA, AakreME, MosesHL: Activation of the ERK pathway is required for TGF-β1-induced EMT in vitro.Neoplasia6, 603–610 (2004).
  • Atfi A , DjelloulS, ChastreE, DavisR, GespachC: Evidence for a role of Rho-like GTPases and stress-activated protein kinase/c-Jun N-terminal kinase (SAPK/JNK) in TGF-β-mediated signaling.J. Biol. Chem.272, 1429–1432 (1997).
  • Hocevar BA , BrownTL, HowePH: TGF-β induces fibronectin synthesis through a c-Jun N-terminal kinase-dependent, Smad4-independent pathway.EMBO J.18, 1345–1356 (1999).
  • Shintani Y , WheelockMJ, JohnsonKR: Phosphoinositide-3 kinase-Rac1-c-Jun NH2-terminal kinase signaling mediates collagen I-induced cell scattering and up-regulation of N-cadherin expression in mouse mammary epithelial cells.Mol. Biol. Cell.17, 2963–2975 (2006).
  • Ke Z , LinH, FanZet al.: MMP-2 mediates ethanol-induced invasion of mammary epithelial cells over-expressing ErbB2.Int. J. Cancer119, 8–16 (2006).
  • Buck MB , KnabbeC: TGF-β signaling in breast cancer.Ann. NY Acad. Sci.1089, 119–126 (2006).
  • Hanahan D , WeinbergRA: The hallmarks of cancer.Cell100, 57–70 (2000).
  • Moreno-Bueno G , PortilloF, CanoA: Transcriptional regulation of cell polarity in EMT and cancer.Oncogene27, 6958–6969 (2008).
  • Ikenouchi J , MatsudaM, FuruseM, TsukitaS: Regulation of tight junctions during the epithelium-mesenchyme transition: direct repression of the gene expression of claudins/occludin by Snail.J. Cell Sci.116, 1959–1967 (2003).
  • Alexandrow MG , KawabataM, AakreM, MosesHL: Overexpression of the c-Myc oncoprotein blocks the growth-inhibitory response but is required for the mitogenic effects of TGF-β.Proc. Natl Acad. Sci. USA92, 3239–3243 (1995).
  • Chen CR , KangY, MassagueJ: Defective repression of c-Myc in breast cancer cells: a loss at the core of the TGF-β growth arrest program.Proc. Natl Acad. Sci. USA98, 992–999 (2001).
  • Smith AP , VerrecchiaA, FagaGet al.: A positive role for Myc in TGF-β-induced Snail transcription and epithelial-to-mesenchymal transition.Oncogene28, 422–430 (2008).
  • Bromberg JF , WrzeszczynskaMH, DevganGet al.: Stat3 as an oncogene.Cell98, 295–303 (1999).
  • Yang Y , PanX, LeiWet al.: Regulation of TGF-β1-induced apoptosis and epithelial-to-mesenchymal transition by protein kinase A and signal transducers and activators of transcription 3.Cancer Res.66, 8617–8624 (2006).
  • Zhao S , VenkatasubbaraoK, LazorJWet al.: Inhibition of STAT3Tyr705 phosphorylation by Smad4 suppresses TGF-β-mediated invasion and metastasis in pancreatic cancer cells.Cancer Res.68, 4221–4228 (2008).
  • Lo HW , HsuSC, XiaWet al.: Epidermal growth factor receptor cooperates with signal transducer and activator of transcription 3 to induce epithelial–mesenchymal transition in cancer cells via up-regulation of TWIST gene expression.Cancer Res.67, 9066–9076 (2007).
  • Ali S , CoombesRC: Endocrine-responsive breast cancer and strategies for combating resistance.Nat. Rev. Cancer2, 101–112 (2002).
  • Coombes RC , GibsonL, HallE, EmsonM, BlissJ: Aromatase inhibitors as adjuvant therapies in patients with breast cancer.J. Steroid Biochem. Mol. Biol.86, 309–311 (2003).
  • Fujita N , JayeDL, KajitaM, GeigermanC, MorenoCS, WadePA: MTA3, a Mi-2/NuRD complex subunit, regulates an invasive growth pathway in breast cancer.Cell113, 207–219 (2003).
  • Dhasarathy A , KajitaM, WadePA: The transcription factor snail mediates epithelial to mesenchymal transitions by repression of estrogen receptor-α.Mol. Endocrinol.21, 2907–2918 (2007).
  • Silveri L , TillyG, VilotteJL, Le ProvostF: MicroRNA involvement in mammary gland development and breast cancer.Reprod. Nutr. Dev.46, 549–556 (2006).
  • Croce CM , CalinGA: miRNAs, cancer, and stem cell division.Cell122, 6–7 (2005).
  • Iorio MV , FerracinM, LiuCGet al.: MicroRNA gene expression deregulation in human breast cancer.Cancer Res.65, 7065–7070 (2005).
  • Blenkiron C , MiskaEA: miRNAs in cancer: approaches, etiology, diagnostics and therapy.Hum. Mol. Genet.16, R106–R113 (2007).
  • Dalmay T , EdwardsDR: MicroRNAs and the hallmarks of cancer.Oncogene25, 6170–6175 (2006).
  • Blenkiron C , GoldsteinLD, ThorneNPet al.: MicroRNA expression profiling of human breast cancer identifies new markers of tumor subtype.Genome Biol.8, R214 (2007).
  • Hurteau GJ , CarlsonJA, SpivackSD, BrockGJ: Overexpression of the microRNA Hsa-miR-200c leads to reduced expression of transcription factor 8 and increased expression of E-cadherin.Cancer Res.67, 7972–7976 (2007).
  • Korpal M , LeeES, HuG, KangY: The miR-200 family inhibits epithelial–mesenchymal transition and cancer cell migration by direct targeting of E-cadherin transcriptional repressors ZEβ1 and ZEB2.J. Biol. Chem.283, 14910–14914 (2008).
  • Gregory PA , BertAG, PatersonELet al.: The miR-200 family and miR-205 regulate epithelial to mesenchymal transition by targeting ZEβ1 and SIP1.Nat. Cell Biol.10, 593–601 (2008).
  • Park SM , GaurAB, LengyelE, PeterME: The miR-200 family determines the epithelial phenotype of cancer cells by targeting the E-cadherin repressors ZEβ1 and ZEB2.Genes Dev.22, 894–907 (2008).
  • Burk U , SchubertJ, WellnerUet al.: A reciprocal repression between ZEβ1 and members of the miR-200 family promotes EMT and invasion in cancer cells.EMBO Rep.9, 582–589 (2008).
  • Ma L , Teruya-FeldsteinJ, WeinbergRA: Tumour invasion and metastasis initiated by microRNA-10b in breast cancer.Nature449, 682–688 (2007).
  • Kong W , YangH, HeLet al.: MicroRNA-155 is regulated by the TGF-β/Smad pathway and contributes to epithelial cell plasticity by targeting RhoA.Mol. Cell. Biol.28, 6773–6784 (2008).
  • Si ML , ZhuS, WuH, LuZ, WuF, MoYY: miR-21-mediated tumor growth.Oncogene26, 2799–2803 (2007).
  • Zhu S , SiML, WuH, MoYY: MicroRNA-21 targets the tumor suppressor gene tropomyosin 1 (TPM1).J. Biol. Chem.282, 14328–14336 (2007).
  • Zhu S , WuH, WuF, NieD, ShengS, MoYY: MicroRNA-21 targets tumor suppressor genes in invasion and metastasis.Cell Res.18, 350–359 (2008).
  • Zavadil J , NarasimhanM, BlumenbergM, SchneiderRJ: TGF-β and microRNA: mRNA regulatory networks in epithelial plasticity.Cells Tissues Organs185, 157–161 (2007).
  • Bakin AV , SafinaA, RinehartC, DaroquiC, DarbaryH, HelfmanDM: A critical role of tropomyosins in TGF-β regulation of the actin cytoskeleton and cell motility in epithelial cells.Mol. Biol. Cell15, 4682–4694 (2004).
  • Varga AE , StourmanNV, ZhengQet al.: Silencing of the tropomyosin-1 gene by DNA methylation alters tumor suppressor function of TGF-β.Oncogene24, 5043–5052 (2005).
  • Zheng Q , SafinaA, BakinAV: Role of high-molecular weight tropomyosins in TGF-β-mediated control of cell motility.Int. J. Cancer122, 78–90 (2008).
  • Lombaerts M , van WezelT, PhilippoKet al.: E-cadherin transcriptional downregulation by promoter methylation but not mutation is related to epithelial-to-mesenchymal transition in breast cancer cell lines.Br. J. Cancer94, 661 (2006).
  • Reynolds PA , SigaroudiniaM, ZardoGet al.: Tumor suppressor p16INK4A regulates polycomb-mediated DNA hypermethylation in human mammary epithelial cells.J. Biol. Chem.281, 24790–24802 (2006).
  • Dumont N , WilsonMB, CrawfordYG, ReynoldsPA, SigaroudiniaM, TlstyTD: Sustained induction of epithelial to mesenchymal transition activates DNA methylation of genes silenced in basal-like breast cancers.Proc. Natl Acad Sci. USA105, 14867–14872 (2008).
  • Singh M , SpoelstraNS, JeanAet al.: ZEβ1 expression in type I versus type II endometrial cancers: a marker of aggressive disease.Mod. Pathol.21, 912 (2008).
  • Shackleton M , VaillantF, SimpsonKJet al.: Generation of a functional mammary gland from a single stem cell.Nature439, 84–88 (2006).
  • Stingl J , RaoufA, EirewP, EavesCJ: Deciphering the mammary epithelial cell hierarchy.Cell Cycle5, 1519–1522 (2006).
  • Villadsen R , FridriksdottirAJ, Ronnov-JessenLet al.: Evidence for a stem cell hierarchy in the adult human breast.J. Cell Biol.177, 87–101 (2007).
  • Mishra L , DerynckR, MishraB: TGF-β signaling in stem cells and cancer.Science310, 68–71 (2005).
  • Ben-Porath I , ThomsonMW, CareyVJet al.: An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors.Nat. Genet.40, 499–507 (2008).
  • Mani SA , GuoW, LiaoMJet al.: The epithelial–mesenchymal transition generates cells with properties of stem cells.Cell133, 704–715 (2008).
  • Morel AP , LievreM, ThomasC, HinkalG, AnsieauS, PuisieuxA: Generation of breast cancer stem cells through epithelial–mesenchymal transition.PLoS ONE3, e2888 (2008).
  • Shipitsin M , CampbellLL, ArganiPet al.: Molecular definition of breast tumor heterogeneity.Cancer Cell11, 259–273 (2007).
  • Farina AR , CoppaA, TiberioAet al.: TGF-β1 enhances the invasiveness of human MDA-MB-231 breast cancer cells by up-regulating urokinase activity.Int. J. Cancer.75, 721–730 (1998).
  • Piek E , JuWJ, HeyerJet al.: Functional characterization of TGF-β signaling in Smad2- and Smad3-deficient fibroblasts.J. Biol. Chem.276, 19945–19953 (2001).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.